Skip to Content
Merck
All Photos(1)

Documents

F0260000

Fluphenazine decanoate

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C32H44F3N3O2S
CAS Number:
Molecular Weight:
591.77
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fluphenazine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

InChI key

VIQCGTZFEYDQMR-UHFFFAOYSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluphenazine decanoate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbonesHealth hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 2 Oral - Repr. 2

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Who receives long-acting antipsychotic medications?
William M Glazer
Psychiatric services (Washington, D.C.), 58(4), 437-437 (2007-04-07)
Branimir Margetić et al.
Psychiatria Danubina, 17(1-2), 94-96 (2006-01-07)
We describe the case of a 39-year-old patient with schizophrenia who developed worsening of glucose metabolism during treatment with two different atypical antipsychotics, clozapine and quetiapine. Diabetes mellitus was recognized during clozapine treatment. During quetiapine treatment, while patient was taking
Switching as only temporal solution for patients with antipsychotic-associated diabetes: further observations.
Branimir Margetić et al.
Psychiatria Danubina, 19(1-2), 87-88 (2007-07-03)
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
Trino Baptista et al.
Schizophrenia research, 89(1-3), 350-352 (2006-10-13)
Martin Turner et al.
International clinical psychopharmacology, 19(4), 241-249 (2004-06-18)
Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone. Participants in this open-label, multicentre, 12-week trial had received flupenthixol decanoate, fluphenazine decanoate, haloperidol decanoate, or

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service